Table 4.
Ongoing studies with bevacizumab and immunotherapies in patients with ovarian cancer (
Source: https://clinicaltrials.gov)
| Study ID (study name) | Phase | Indication | Combination regimen being investigated | Comparator arm(s) | N | Primary endpoint | Expected completion date |
|---|---|---|---|---|---|---|---|
| First-line therapy | |||||||
| NCT03038100 (IMagyn050) | III | Newly diagnosed Stage III-IV OC, primary peritoneal cancer and/or fallopian tube cancer | Bevacizumab + atezolizumab + CT | Bevacizumab + CT | 1300 | PFS and OS | December 2021 |
| Relapsed, platinum-sensitive ovarian cancer | |||||||
| NCT02891824 (ENGOT Ov29/ATALANTE) | III | Platinum-sensitive recurrent epithelial OC, primary peritoneal cancer and/or fallopian tube cancer with platinum-free interval > 6 months) | Bevacizumab + atezolizumab + CT | Bevacizumab + CT | 405 | PFS | September 2023 |
| NCT03596281 (PEMBOV) | I | Recurrent platinum-sensitive OC, primary peritoneal cancer and/or fallopian tube cancer | Bevacizumab + pembrolizumab | Pembrolizumab + PEG-liposomal doxorubicin | 40 | DLT | June 2024 |
| Relapsed platinum-resistant or refractory ovarian cancer | |||||||
| NCT03353831 (AGO-OVAR 2.29) | III | Recurrent OC, fallopian tube, or primary peritoneal cancer with 1st or 2nd relapse < 6 months after platinum-based chemotherapy or 3rd relapse | Atezolizumab + bevacizumab + CT | Bevacizumab + CT | 664 | OS and PFS | September 2022 |
| NCT03574779 | II | Recurrent PARP inhibitor-naïve, platinum-resistant OC, primary peritoneal cancer and/or fallopian tube cancer | Bevacizumab + TSR-042 (PD-1 inhibitor) + niraparib | – | 40 | ORR | June 2020 |
| NCT03363867 (BEACON) | II | C1 subtype of platinum-resistant or refractory recurrent OC, fallopian tube or peritoneal cancer | Bevacizumab + atezolizumab + cobimetinib | – | 29 | ORR | July 2020 |
| NCT02659384 | II | Recurrent platinum-resistant advanced or metastatic OC, fallopian tube or peritoneal cancer | Atezolizumab + bevacizumab ± aspirin |
Bevacizumab Atezolizumab ± aspirin |
160 | PFS | January 2021 |
| NCT02923739 | II | Platinum-resistant recurrent epithelial OC, primary peritoneal cancer and/or fallopian tube cancer | Bevacizumab + emactuzumab + paclitaxel | Bevacizumab + paclitaxel | 121 | Safety and PFS | May 2025 |
| Relapsed ovarian cancer, either platinum sensitive or platinum resistant | |||||||
|
(results available [107]) |
II | Recurrent OC, fallopian tube or primary peritoneal cancer | Bevacizumab + pembrolizumab + cyclophosphamide | – | 40 | AEs and PFS | March 2019 |
| NCT02873962 | II | Recurrent OC, fallopian tube or peritoneal cancer | Bevacizumab + nivolumab | – | 38 | ORR | February 2024 |
| Relapsed ovarian cancer, platinum-sensitivity status unclear | |||||||
| NCT03197584 (QUILT-3.051) | Ib/II | Recurrent epithelial OC | Bevacizumab + avelumab + CT + cancer vaccines | – | 67 | AEs and ORR | April 2019 |
AE adverse event; CT chemotherapy; DLT dose-limiting toxicity; ID identifier; OC ovarian cancer; ORR objective response rate; OS overall survival; PEG pegylated; PFS: progression-free survival